These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 7507397)

  • 1. Neuronal damage induced by beta-N-oxalylamino-L-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
    Willis CL; Meldrum BS; Nunn PB; Anderton BH; Leigh PN
    Brain Res; 1993 Nov; 627(1):55-62. PubMed ID: 7507397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effect of free radical scavengers on beta-N-oxalylamino-L-alanine (BOAA)-induced neuronal damage in rat hippocampus.
    Willis CL; Meldrum BS; Nunn PB; Anderton BH; Leigh PN
    Neurosci Lett; 1994 Dec; 182(2):159-62. PubMed ID: 7536312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus.
    Moncada C; Arvin B; Le Peillet E; Meldrum BS
    Neurosci Lett; 1991 Dec; 133(2):287-90. PubMed ID: 1816508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline protects against both AMPA and kainate-induced lesions in rat striatum in vivo.
    Massieu L; Tapia R
    Neuroscience; 1994 Apr; 59(4):931-8. PubMed ID: 7520137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of NBQX on the distal and local toxicity of glutamate agonists administered intra-hippocampally.
    Lees GJ; Leong W
    Brain Res; 1993 Nov; 628(1-2):1-7. PubMed ID: 7508807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-N-oxalylamino-L-alanine action on glutamate receptors.
    Ross SM; Roy DN; Spencer PS
    J Neurochem; 1989 Sep; 53(3):710-5. PubMed ID: 2547898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation.
    Foster AC; Gill R; Woodruff GN
    J Neurosci; 1988 Dec; 8(12):4745-54. PubMed ID: 2904493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures.
    Kristensen BW; Noraberg J; Zimmer J
    Brain Res; 2001 Oct; 917(1):21-44. PubMed ID: 11602227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
    Parsons CG; Gruner R; Rozental J
    Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NBQX prevents contralateral but not ipsilateral seizure-induced cytotoxicity of kainate but not AMPA-reversal at high doses of NBQX.
    Lees GJ; Leong W
    Neuroreport; 1994 Oct; 5(16):2153-6. PubMed ID: 7532455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia.
    Nellgård B; Wieloch T
    J Cereb Blood Flow Metab; 1992 Jan; 12(1):2-11. PubMed ID: 1345757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h.
    Sheardown MJ; Suzdak PD; Nordholm L
    Eur J Pharmacol; 1993 Jun; 236(3):347-53. PubMed ID: 7689464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal damage and MAP2 changes induced by the glutamate transport inhibitor dihydrokainate and by kainate in rat hippocampus in vivo.
    Arias C; Arrieta I; Massieu L; Tapia R
    Exp Brain Res; 1997 Oct; 116(3):467-76. PubMed ID: 9372295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures.
    Blaabjerg M; Kristensen BW; Bonde C; Zimmer J
    Brain Res; 2001 Apr; 898(1):91-104. PubMed ID: 11292452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy between diazepam and NBQX in preventing neuronal death caused by non-NMDA agonists.
    Lees GJ; Leong W
    Neuroreport; 1994 Oct; 5(16):2149-52. PubMed ID: 7532454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices.
    Pai KS; Shankar SK; Ravindranath V
    Neurosci Res; 1993 Aug; 17(3):241-8. PubMed ID: 7901822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline.
    Bernert H; Turski L
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5235-40. PubMed ID: 8643559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate.
    Greene JG; Greenamyre JT
    J Neurochem; 1995 May; 64(5):2332-8. PubMed ID: 7536810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domoic acid neurotoxicity in cultured cerebellar granule neurons is mediated predominantly by NMDA receptors that are activated as a consequence of excitatory amino acid release.
    Berman FW; Murray TF
    J Neurochem; 1997 Aug; 69(2):693-703. PubMed ID: 9231729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion.
    DeGiorgio LA; DeGiorgio N; Volpe BT
    Neuroscience; 1999 Apr; 90(1):79-85. PubMed ID: 10188935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.